OxTalks is Changing
OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Can we re-medicalise psychedelic experience?
Background:
Psilocybin has demonstrated apparent antidepressant effects in pilot studies with depressed patients, but RCT evidence for its effect in treatment-resistant depression has been lacking. Treatment resistance is common, carries significant morbidity and next step treatments are often unsatisfactory.
Methods:
We performed a double-blind, parallel-group trial to evaluate the safety and efficacy of psilocybin in adults with treatment-resistant major depressive disorder, randomized 1:1:1 to a single dose of psilocybin (25mg, 10mg, 1mg), with psychological support.
Results:
A total of 79 patients were assigned to psilocybin 25mg, 75mg, 10mg, and 79 to 1 mg. Mean week 3 change in the MADRS for psilocybin 25 mg and 10 mg dose groups versus 1 mg were – 12.0 and -7.9 versus -5.4 points (least-squares mean difference for the 25 mg and 10 mg doses versus the 1 mg dose was -6.6 points: 95% CI, -10.2 to 2.9, P<0.001; and -2.5 points, 95% CI, -6,2 to 1.2; not significant). Sustained response rates at week 12 were 34.8% for psilocybin 25mg, 9.1% for 10 mg, and 18.2% for 1 mg. The number of patients discontinuing due to an adverse event on psilocybin 25 mg, 10 mg and 1 mg was n=2,2, and 4, respectively. The relationship between positive psychedelic experience and clinical outcomes supports the dose-related effect seen in the primary analysis.
Conclusions:
The efficacy and acceptability demonstrated in this Phase IIb trial support the further development of psilocybin for treatment-resistant depression. The proposed phase 3 clinical programme will be described.
Date:
7 February 2023, 9:30
Venue:
Department of Psychiatry, Headington OX3 7JX
Venue Details:
Seminar Room
Speaker:
Professor Guy Goodwin (University Department of Psychiatry, Oxford )
Organising department:
Department of Psychiatry
Organiser contact email address:
rania.elgarf@psych.ox.ac.uk
Part of:
Psychiatry Seminar Series
Booking required?:
Not required
Audience:
Members of the University only
Editors:
Diana Verley,
Rania Elgarf
